Respiratory Disease Vaccine: A Leading Driver Behind The Rising Incidence Of Tuberculosis Drives Growth In The Respiratory Disease Vaccine Market Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Will the Respiratory Disease Vaccine Industry Market Size Be by 2025?
In the past few years, the size of the respiratory disease vaccine market has experienced a slight increase. It is projected to rise from $69.99 billion in 2024 to $70.9 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 1.3%. Factors such as a growing prevalence of respiratory diseases, heightened public consciousness regarding vaccination, public health campaigns, and a widening demand for efficient and more manageable vaccines have contributed to this growth in the historical phase.

What's the Long-Term Growth Forecast for the Respiratory Disease Vaccine Market Size Through 2029?
The market size of the respiratory disease vaccine is predicted to exhibit a consistent expansion in the upcoming years, reaching a value of $79.16 billion by 2029 with a CAGR of 2.8%. The surge during the forecasted phase can be traced back to factors such as an aging demographic, an increase in healthcare expenditure, investments funnelled into vaccines, and readiness for potential pandemics. The forecasted time frame will also see significant trends like innovative vaccine solutions, cooperative research, progression in vaccine formulation, and authorization of drugs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What Are the Key Growth Drivers Fueling the Respiratory Disease Vaccine Market Expansion?
The escalating cases of tuberculosis are anticipated to fuel the expansion of the market for respiratory disease vaccines. Tuberculosis (TB), a respiratory ailment caused by the Mycobacterium tuberculosis bacterium, primarily targets the lungs and could potentially compromise other systems and organs, resulting in a variety of issues. The surge in tuberculosis cases could accelerate the production and distribution of vaccines for respiratory diseases, in an effort to curb TB proliferation. For instance, statistics from the US-based government agency, Centers for Disease Control and Prevention, reveal that there were 8,331 tuberculosis (TB) cases reported in the United States in 2022, signifying a 5.9% growth in the case tally compared to 2021. The incidence rate escalated to 2.5 cases for every 100,000 individuals, showing a 5.5% upsurge from the year before. Consequently, the mounting cases of tuberculosis will be a driving force for the market for respiratory disease vaccines. The rising prevalence of smoking is predicted to accelerate the expansion of the market for respiratory disease vaccines. Smoking pertains to inhaling and exhaling smoke generated by burning tobacco or tobacco-containing products, which pose a variety of health threats, such as tracheitis, heart diseases, stroke, and cancer. Vaccines for respiratory diseases can offer a certain level of protection against specific infections prevalent among smokers. For instance, information sourced from Statistics Canada, a governmental agency in Canada, indicates that cigarette production rose by 5.8% compared to June 2021. Furthermore, the total quantity of cigarettes sold witnessed a 1.3% rise from May 2022, amounting to 1.4 billion in June 2022. Hence, the escalating prevalence of smoking is fueling the growth of the market for respiratory disease vaccines.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What Are the Key Trends Driving Respiratory Disease Vaccine Market Growth?
Leading corporations active in the respiratory disease vaccine market are focusing on developing cutting-edge products to boost their effectiveness and deliver superior solutions for the prevention and treatment of respiratory disease infections. For example, in May 2023, Pfizer Inc., a pharmaceutical company based in the US, secured approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), the dual respiratory syncytial virus prefusion F (RSVpreF) vaccine, intended to prevent lower respiratory tract disease instigated by respiratory syncytial virus in individuals aged 60 and above. ABRYSVO, which is an unadjuvanted vaccine consisting of two preF proteins designed to optimize immunity to RSV A and B types, has clinically demonstrated safety and efficiency.

How Is the Respiratory Disease Vaccine Market Segmented?
The respiratory disease vaccine market covered in this report is segmented -

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Companies Are Leading the Charge in Respiratory Disease Vaccine Market Innovation?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Which Regions Are Leading the Global Respiratory Disease Vaccine Market in Revenue?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.